Everything below concerns triple agonist. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-05-22. Where a claim depends on a specific study, the study is described rather than over-claimed.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
| Property | Value | Notes |
|---|---|---|
| Compound class | Synthetic triple-agonist peptide | Single linear chain carrying three receptor activities |
| Reported molecular weight | Approximately 4731 Da | Calculated from the published sequence; sources vary slightly |
| Appearance | White to off-white lyophilized powder | Typical of purified research-grade peptides |
| Solubility | Freely soluble in water; poorly soluble in nonpolar solvents | Dissolves in aqueous buffer near neutral pH |
| Storage of dry powder | -20 °C or below, desiccated, protected from light | Avoid repeated temperature cycling |
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
==== Andrea Cozzolino ==== Andrea Cozzolino's legal immunity was also removed by the European Parliament on 2 February 2023, when Andrea Cozzolino was in Italy. Cozzolino was arrested on 10 February 2023, after leaving a hospital in Naples where he was being treated for heart problems; he was taken to Poggioreale prison, but later allowed to go home under house-arrest. Cozzolino's lawyer Dimitri De Béco issued a statement that Cozzolino opposed being extradited to Belgium, because of the Belgian justice "way of proceeding". Cozzolino has repeatedly denied any wrong-doing. On 14 February, a Naples court granted a request from Cozzolino's lawyers to postpone the extradition hearing to 28 February so that the court could check the prison in Belgium that Cozzolino would be put in if extradited. In June he flew to Brussels and was placed by a Judge on parole, with conditions attached.
In order to reach the maximum efficacy to eradicate biofilms, therapeutic strategies need to target both the biofilm matrix components as well as the embedded microorganisms to target the complex biofilm microenvironment.
Bolsonaro continually accused political opponents and the press of exaggerating the threat of the virus and called it a "fantasy" created by the media. In August 2020, in the middle of the pandemic, Bolsonaro's approval rating showed signs of recovery, reaching its highest level since his inauguration. In November 2020 he said he would not take a COVID vaccine if it became available, but he later said he would support any possible vaccine if the Brazilian Health Agency deemed it safe. In the same broadcast, he called face masks "the last taboo to fall". In 2020 the Organized Crime and Corruption Reporting Project (OCCRP), an international non-governmental organization that investigates crime and corruption, gave Bolsonaro its Person of the Year Award, which "recognizes the individual who has done the most in the world to advance organized criminal activity and corruption". Bolsonaro received the award for "surrounding himself with corrupt figures, using propaganda to promote his populist agenda, undermining the justice system, and waging a destructive war against the Amazon region that has enriched some of the country's worst land owners".
=== Triggers === A known precipitating event can be found in over 90% of episodes of adrenal crisis. The most common cause of adrenal crisis is infections, specifically gastrointestinal infections. Adrenal crises can also be caused by major surgery, dental operations, pregnancy/labour, extreme weather, serious injury/accidents, intense physical activity, vaccines, and emotional stress. Those who have autoimmune polyendocrine syndrome type 2 might have both thyroid and adrenal insufficiency. Levothyroxine can speed up the metabolism of cortisol and trigger an adrenal crisis. Several medications, including chemotherapy and immunotherapy, have been linked to an increased risk of adrenal crisis. Immune checkpoint inhibitors are known to cause endocrine problems, including hypophysitis and adrenalitis, with subsequent adrenal insufficiency. Barbiturates and adrenostatic medications may raise the risk of an adrenal crisis. Cytochrome P450 3A4 inducers boost hydrocortisone metabolism, leading to a higher demand for hydrocortisone since hydrocortisone is being metabolized faster.
When measured by fatalities per person transported, however, buses are the safest form of transportation. The number of air travel fatalities per person are surpassed only by bicycles and motorcycles. This statistic is used by the insurance industry when calculating insurance rates for air travel. For every billion kilometers traveled, trains have a fatality rate that is 12 times higher than that of air travel, and the fatality rate for automobiles is 62 times greater than for air travel. By contrast, for every billion journeys taken, buses are the safest form of transportation; using this measure, air travel is three times more dangerous than car transportation, and almost 30 times more dangerous than travelling by bus. A 2007 study by Popular Mechanics magazine found that passengers sitting at the back of an aeroplane are 40% more likely to survive a crash than those sitting at the front. The article quotes Boeing, the FAA, and a website on aircraft safety, all of which claim that there is no "safest" seat. The study examined 20 crashes, not taking into account the developments in safety after those accidents. However, a flight data recorder is usually mounted in the aircraft's empennage (tail section) where it is more likely to survive a severe crash. Between 1983 and 2000, the survival rate for people in U.S. plane crashes was greater than 95 percent.
Sources: en.wikipedia.org
For SNP annotation, many kinds of genetic and genomic information are used. Based on the different features used by each annotation tool, SNP annotation methods may be split roughly into the following categories: Genomic information from surrounding genomic elements is among the most useful information for interpreting the biological function of an observed variant. Information from a known gene is used as a reference to indicate whether the observed variant resides in or near a gene and if it has the potential to disrupt the protein sequence and its function. Gene based annotation is based on the fact that non-synonymous mutations can alter the protein sequence and that splice site mutation may disrupt the transcript splicing pattern.
Post-SSRI sexual dysfunction (PSSD) is an iatrogenic condition in which sexual side effects persist after discontinuation of serotonin reuptake inhibiting antidepressants, including venlafaxine. Characteristic symptoms include genital numbness, pleasureless or weak orgasm, loss of libido, and erectile dysfunction; non-sexual symptoms such as emotional blunting and cognitive impairment may also occur. The condition can arise after even brief exposure to a serotonin reuptake inhibitor and may persist indefinitely; there is currently no established treatment. A case study published in 2023 specifically documented PSSD symptoms—including low libido, delayed ejaculation, and erectile dysfunction—developing after discontinuation of venlafaxine, with 5-HT1A receptor downregulation proposed as a possible mechanism. A 2023 retrospective cohort study of over 12,000 males estimated the risk of irreversible sexual dysfunction (as measured by persistent need for phosphodiesterase inhibitors after antidepressant cessation) at approximately 0.46% of patients treated with serotonergic antidepressants, including SNRIs. The DSM-5 noted in 2013 that serotonin reuptake inhibitor–induced sexual dysfunction may persist after the agent is discontinued. In 2019, the European Medicines Agency's Pharmacovigilance Risk Assessment Committee recommended that product labels for all SSRIs and SNRIs, including venlafaxine, be updated to warn that sexual dysfunction may be long-lasting after treatment is stopped.
kill (90% of organisms killed in every step), tedizolid fAUC24/MIC in neutropenic mouse models with a thigh infection with VRE and MRSA should be 14.2 and 138.5, respectively. The post-antibiotic effects of tedizolid against VRE and MRSA are 2.39 and 0.99 h, respectively.
=== Venezuela === Bolivarian Chavismo and its supporters have declared their contempt for the Peruvian government for, according to then-Venezuelan Foreign Minister Delcy Rodríguez in 2017, supporting "Venezuela's intervention in the world" due to the creation of the Lima Group. It has also been increased by the Venezuelan authorities, such as President Nicolás Maduro describing Peru as having an "imperialist mentality" and "lifelong anti-Bolivarian" for not being invited to the VIII Summit of the Americas held in Lima due to the crisis in Venezuela. Likewise, during the Peruvian Immigration in Venezuela, many Peruvians, as well as Ecuadorians and Colombians, were subjected to discrimination and xenophobia by the Venezuelan socialist government, who used the adjectives "Indian" and "guajiro" to refer to immigrants from these countries. Anti-Peruvianism has also intensified in the Venezuelan population, which has a negative perspective against Peruvians due to accusations of xenophobia during Venezuelan Immigration in Peru, and which has generated a belief that Peruvians have been ungrateful to Venezuela after welcome them during the Peruvian exodus from the time of terrorism. Many anti-Peruvian prejudices and stereotypes have also been shown among Venezuelans, where they accuse Peruvians of being ugly people and the face of Indians, affirming that their migrants come to "improve the race". It is also often accused that figures of the Venezuelan government have had anti-Peruvian tendencies, and some historical figures of the colonial era, being some such as:
Sources: en.wikipedia.org
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.
No. As of the most recent public information it remains investigational in every jurisdiction. Material sold under this name outside trials is a research chemical, not an approved medicine. Current status should always be checked against regulator notices.
Dual agonists act on two receptors, usually GIP and GLP-1. Retatrutide adds glucagon receptor activity, which is associated with increased energy expenditure. Whether that third component adds clinically meaningful benefit over dual agonism remains an open question.
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.